Clinical Trial Update: N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for N-Carbamylglutamate (Carbaglu) in the treatment of hyperammonemia due to inborn errors of metabolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperammonemia
• Inborn Errors of Metabolism

Drugs mentioned

• N-Carbamylglutamate (N-carbamylglutamate)

Snippet

Sponsor: Mendel Tuchman | Conditions: Inborn Errors of Metabolism | Phase 2, Phase 3 | Status: UNKNOWN